A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Exclusion Criteria

• •Participants who have disease progression after treatment with available therapies that are known to confer clinical benefit or who are intolerant to treatment.
• •Willingness and ability to safely undergo pretreatment and on-treatment tumor biopsies (core or excisional).
• •Eastern Cooperative Oncology Group performance status 0 or 1.
• •Willingness to avoid pregnancy or fathering children based on protocol-defined criteria.
• •Laboratory values at screening outside the protocol-defined ranges.
• •Administration of colony-stimulating factors within 14 days before Study Day 1.
• •Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.
• •Receipt of a live vaccine within 30 days of planned start of study drug.
• •Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox/zoster, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines are live-attenuated vaccines and are not allowed.
• •Active autoimmune disease that required systemic treatment in the past (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).
• +8 more criteria